Harrow, Inc. · NASDAQ:HROW
Harrow — Imprimis Pharmaceuticals — Investor Presentation (January 2018)
20 slides from Harrow's investor presentation, Jan 9, 2018
Slide 1: Imprimis Pharmaceuticals January 2018
NASDAQ: IMMY January 2018 IMmprimis
Slide 2: Safe Harbor
Safe Harbor This presentation contains express “forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. You are cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assump
Slide 3: Introduction to Imprimis Pharmaceuticals
Introduction to Imprimis Pharmaceuticals Imprimis is one of the largest specialized compounded drug businesses in the US Serve unmet needs by compounding new drugs from bulk active drug ingredients IP focused with 60+ formulation composition and method patent filings Monetize IP portfolio through co
Slide 4: Imprimis
Imprimis
Slide 5: Imprimis Rx Value Chain
Imprimis R Value Chain Payment Hospital or ASC Physician and Institution Benefits No insurance company, pharmacy benefit manager (PBM), wholesaler or distributor middlemen No formulary rejections, discount cards or rebates No payment submittals, investigations or PBM clawbacks Direct access to drug
Slide 6: Ophthalmology Market Data
imprimis Ophthalmology Market Data Opportunity in US $1 billion drug market ~4.6M ocular surgeries and other procedures*"# Demographic growth in the overall market ~6% per yr $2 billion drug market 19+ million targeted prescriptions? 4 million Americans'® $2 billion drug market 4 million prescriptio
Slide 7: Imprimis Rx Formulations For Individual Patients
Imprimis cm Formulations For Individual Patients Proprietary formulations include: Latanoprost (preservative-free) Whatis it: = Chronic care compounded ophthalmic drugs Why is it important: = Compounded solutions for unmet market needs = Value Proposition: = Combine multiple medicines into one bottl
Slide 8: Imprimis Rx Formulations For Office Use
Imprimis R Formulations For Office Use Proprietary formulations include: Prednisolone acetate + gatifloxacin Prednisolone acetate + gatifloxacin + bromfenac Prednisolone acetate + bromfenac Midazolam + ketamine HCI + ondansetron Whatis it: = Cost effective suite of preoperative, intraoperative, and
Slide 9: Eton, Surface
Cant. elon Gu trface
Slide 10: Eton Pharmaceuticals, Inc. Spin-Out
Eton Pharmaceuticals, Inc. Spin-Out What is it? elon = 505(b)(2) company with 10 pipeline drug assets = Spun-out of Imprimis June 2017 ($20M Series A) = Strong management team with a history of success pharmaceuticals Why is it important? = Imprimis holds passive 27% equity stake in Eton = 6% royalt
Slide 11: Surface Pharmaceuticals, Inc. Subsidiary
Surface Pharmaceuticals, Inc. Subsidiary What is it? = 505(b)(2) company with three pipeline drug assets = Focus on ocular surface disease market (Dry Eye) = Strong management and Board of Directors team with a history of success = May pursue spin-off transaction similar to Eton Why is it important?
Slide 12: Park Compounding, Inc. Subsidiary
Park Compounding, Inc. Subsidiary 7 Whatis it: VW = Customizable pharmaceutical compounding wholly owned subsidiary PARK Focused on integrative and other medicines for oncology, autoimmune diseases and chronic COMPOUNDING infectious diseases = Incubator of new drug formulation ideas from physician c
Slide 13: Slide 13
Slide 14: Imprimis Value Summary
© 6 8 O IMpriMIS pValue Summary Largest Ophthalmology Compounding Business in the US Disrupting the U.S. ophthalmic drug markets with novel compounded formulations = Ophthalmic Surgery $1B market * Glaucoma $2B+ market = Dry Eye $2B market = Over 1,700 ophthalmology customers and growing Products an
Slide 15: Company Profile
Company Profile IMPFIMIS 2 Trading symbol: NASDAQ: IMMY Price per share (12-5-2017): $1.82 Stock price range (52-week): $1.35 - $4.69 Avg. daily Q4 trading volume: 595,000 shares Market cap: $37 million Shares Outstanding: 20.5 million Insider Beneficial Ownership: 13% “Participation by CEO, CFO, Di
Slide 16: References and Appendix
Slide 17: References
References 1. Market Scope, LLC, Comprehensive Report on the Global IOL Market (2013, May). 2. Number of LASIK surgeries in the United States from 1996 to 2020. Retrieved February 9, 2016 from https://wwnw statista com/statistics/271478/number-oflasik-surgeries-in-the-us/ Imprimis Pharmaceuticals in
Slide 18: Drug Combination IP
Drug Combination IP (7) » a Tameinolone Act \oxifloxacin HCl 18/1)mg/mL Sterié? imprimis SSP Technology® allows for mixing of active drugs into suspensions for: Cataract surgery Refractive surgery Without SSP Technology®, large irregular clumps of active drugs persist, not usable as injection or eye
Slide 19: Published Clinical Data
Published Clinical Data Tyson, S.L., et al. (2017, January). Clinical outcomes after injection of a compounded pharmaceutical for prophylaxis after cataract surgery: a large-scale review. Current Opinion in Ophthalmology. No major intraoperative complications associated with the transzonular injecti
Slide 20: Imprimis Pharmaceuticals
IMmprimis Imprimis Pharmaceuticals (NASDAQ: IMMY) 12264 El Camino Real, #350 San Diego, CA 92130 (858) 704-4040
Imprimis Pharmaceuticals — Investor Presentation (January 2018) on 6ix